EGFR and non-small cell lung carcinoma: In this regard, the found genetic portrait of cancer cells may mirror the underlying tumor heterogeneity, thus allowing to ultra-stratifying those EGFR mutant NSCLC patients, and estimating a differential clinical benefit of anti-EGFR TKIs in such already-selected subpopulation.